Advisory Committees Free Of Conflicts May Be Unfeasible, FDA Review Says
This article was originally published in The Tan Sheet
Executive Summary
FDA's policy of granting waivers for financial conflicts of interest for advisory committee members is supported by an independent review commissioned by the agency, which determined that constructing advisory committees free from conflicts of interest would be expensive and time-consuming and may be unfeasible for certain topics and fields of expertise
You may also be interested in...
Advisory Committee Policy Allows Members With Financial Conflicts To Vote
FDA advisory committee participants with personal financial conflicts of interest may fully participate in committee meetings, according to the agency's latest conflict of interest policy
Advisory Committee Policy Allows Members With Financial Conflicts To Vote
FDA advisory committee participants with personal financial conflicts of interest may fully participate in committee meetings, according to the agency's latest conflict of interest policy
Advisory Committee Policy Allows Members With Financial Conflicts To Vote
FDA advisory committee participants with personal financial conflicts of interest may fully participate in committee meetings, according to the agency's latest conflict of interest policy